Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $60.0 million.

  • Gyre Therapeutics' Cash & Current Investments rose 13899.15% to $60.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.0 million, marking a year-over-year increase of 13899.15%. This contributed to the annual value of $26.7 million for FY2024, which is 2028.11% down from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Cash & Current Investments is $60.0 million, which was up 13899.15% from $54.4 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Cash & Current Investments registered a high of $131.0 million during Q1 2021, and its lowest value of $6.9 million during Q3 2023.
  • In the last 5 years, Gyre Therapeutics' Cash & Current Investments had a median value of $33.5 million in 2023 and averaged $43.8 million.
  • In the last 5 years, Gyre Therapeutics' Cash & Current Investments plummeted by 8470.95% in 2023 and then soared by 26456.76% in 2024.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Cash & Current Investments stood at $49.4 million in 2021, then tumbled by 48.99% to $25.2 million in 2022, then surged by 33.1% to $33.5 million in 2023, then decreased by 20.28% to $26.7 million in 2024, then surged by 124.79% to $60.0 million in 2025.
  • Its Cash & Current Investments stands at $60.0 million for Q3 2025, versus $54.4 million for Q2 2025 and $29.9 million for Q1 2025.